Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients...

Revolution Medicines Snags One of First New FDA Vouchers to Speed Review

Revolution Medicines, which is developing targeted therapies for RAS-addicted cancers, has received one of the first U.S. Food and Drug Administration (FDA) non-transferrable vouchers under the new Commissioner’s National Priority Voucher (CNPV) pilot program. The voucher, aimed at accelerating approval time dramatically, is for daraxonrasib (RMC-6236), Revolution’s oral, direct RAS(ON), multi-selective inhibitor. RAS has been amongst the most n…

First Commissioner’s National Priority Vouchers Awarded to Investigational, International, and Generic Drugs

The inaugural distribution of Commissioner’s National P […] The post First Commissioner’s National Priority Vouchers Awarded to Investigational, International, and Generic Drugs first appeared on GeneOnline News. The post First Commissioner’s National Priority Vouchers Awarded to Investigational, International, and Generic Drugs appeared first on GeneOnline News.

Non-transferrable CNPV voucher awarded — Revolution Medicines' daraxonrasib (RMC-6236) in Phase 3 with 2026 readout

Revolution Medicines received a non-transferrable Commissioner's National Priority Voucher for daraxonrasib (RMC-6236). The drug is in two global Phase 3 trials (RASolute 302, RASolve 301) and has Breakthrough Therapy Designation; RASolute 302 data readout expected in 2026.